ADVA-OPTICAL-NETWORKING
14.10.2021 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that i3D.net has deployed its FSP 3000 TeraFlex™ to enhance the experience of the 50 million online gamers that i3D.net serves every day. The technology enables the leading hosting solutions provider for the gaming industry to meet rising data demand and customer expectation by significantly increasing capacity and reducing latency in its global transport network. ADVA’s highly flexible solution enables i3D.net to harness previously unused spectrum, optimizing all optical paths and unlocking new value in its existing fiber infrastructure. The TeraFlex™ terminal will also benefit i3D.net’s enterprise customers, who will be able to leverage low-latency video conferencing applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005058/en/
“As one of the world’s leading high-performance hosting providers, we’re constantly striving to deliver an unbeatable experience for end users. That means investing in the most advanced technology on the market. With our new infrastructure built on the ADVA FSP 3000 TeraFlex™ , we’re removing any bottlenecks by massively increasing the capacity of our network. And, thanks to its ultra-flexible coherent interfaces with fractional QAM, it ensures maximum data throughput over every link,” said Edwin Verwoerd, VP, engineering, i3D.net. “Low latency is our business, and that’s precisely what our new solution offers. It enables us to provide a winning edge to both players and businesses.“
i3D.net’s specific configuration of the ADVA FSP 3000 TeraFlex™ is able to carry up to 400Gbit/s of data per wavelength and 800Gbit/s per sled. This open and ultra-flexible 1RU terminal uses software-defined fractional QAM modulation and adaptive baud rate capabilities. As well as significantly boosting the capacity of i3D.net’s worldwide infrastructure, the ADVA FSP 3000 TeraFlex™ ensures the lowest cost per bit for every fiber path. What’s more, it offers advanced streaming telemetry. This provides operators with real-time performance data, helping them to ensure the highest levels of availability and quality of service for end users. The new solution also features other components of ADVA’s FSP 3000 open optical transport solution , including FSP 3000 QuadFlex™ optical terminals.
“Our FSP 3000 TeraFlex™ will be a vital tool for i3D.net. It will be key to seizing new opportunities during the global gaming boom and providing unprecedented levels of quality for its customers. The innovative terminal offers excellent space- and power-efficiency while maximizing fiber utilization. With its flexible bandwidth modulation, it ensures optimal performance even over long-distance links. That’s why our high-performance TeraFlex™ is ideal for supporting satisfying, immersive gaming,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “It’s great to see another major operator harnessing our TeraFlex™ technology to unlock extra value in its infrastructure. Spread across six continents, i3D.net’s network will now deliver even more for its customers.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About i3D.net
i3D.net – a Ubisoft company, is one of the leading providers of high-performance hosting and global infrastructure services. We operate a global low-latency network with thousands of servers spread over 40+ point of presence on 6 continents. i3D.net excels in the gaming market and hosts a variety of AAA games. Our mission is to bring the lowest latency to as many users around the world as possible, with the goals of reaching 1 billion users on our platforms by 2025. For more information visit www.i3d.net .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005058/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom